HER2 therapies and gastric cancer: A step forward

作者：de Mello Ramon Andrade^*; Marques Andrea Marin; Araujo Antonio

来源：World Journal of Gastroenterology, 2013, 19(37): 6165-6169.

DOI：10.3748/wjg.v19.i37.6165

• Gastric cancer
• Trastuzumab
• c-Met
• Human epidermal growth factor receptor 2
• Lapatinib
• Pertuzumab

Gastric cancer usually is diagnosed in advanced stages and thus current medical practice affords limited therapeutic options. However, recent studies established the role of human epidermal growth factor receptor 2 (HER2) in clinical management. Trastuzumab, an anti-HER2 monoclonal antibody, acquired a main role in advanced gastric cancer harboring HER2 overexpression and/or amplification improving survival to 17.1 mo according to trastuzumab for gastric cancer phase III trial results. Also, new promising drugs, such as c-Met inhibitors, are in development and assessment for this setting. Certainly, novel drugs will emerge in the next feel years for help oncologists improve clinical management of advanced gastric cancer providing higher survival and quality of life. In this mini-review we will discuss some issues in this regard and provide an actual overview of this setting.

• 出版日期2013-10-7